![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, November 30, 2017 5:54:38 PM
1. I'm hardly being myopic, I'm looking at the data, please of course feel free to show were I am incorrectly quoting data.
2. I apologise that I didn't mention about Cleveland Biolabs Entolimod, but as you can mentioned I clearly brought it forwards for you and further noted that this wasn't mentioned because the Entolimod Data definitely appears poor. I'm hardly going to bring up companies where the data shows that don't seem to be important competition. Again in my reserach I referenced the Entolimod research paper itself, so hardly being biased there.
3. PSTI current burn you say is 20 million per quarter??? Where did you get that from? If you look at their most recent financial update from November 14 2017, just over 1 month ago, they clearly state " The Company’s net cash used for operating activities for the quarter ended September 30, 2017 was $5.2 million"
Thus their current quarterly burn is circa 5.2 million USD.
http://www.pluristem.com/wp-content/uploads/2017/11/Q1_2018_Highlights_final_isa.pdf
Seems like you're the one either with the wrong recent information information or that you have a biased outlook?
and Finally, with regards their financial position, that is a good point to bring up. Let us investigate that:
As per the financial highlights release I mention of November 14th. They mentioned they had 21.3 million as of September 30th 2017.
Now lets suppose that with a 5 million per quater burn, they would currently have 19 million of this.
Then we add 8.7 million from Horizon 2020 award, for the Phase III Hip-Fracture trial.
http://www.pluristem.com/wp-content/uploads/2017/09/Hip-Fracture-trial-status_final.pdf
Then we add the 15.1 million from the Isreal raise
http://www.pluristem.com/wp-content/uploads/2017/10/Israeli-Public-Offering_final.pdf
Then we remind ourselves of the 7.9 million again from Horizon 2020 to further develop the PLX-PAD program via nTrack, of which a few million will go to PSTI, let''s just go with 2 million.
http://www.pluristem.com/wp-content/uploads/2017/10/nTRACK-Grant-Press-Release-_final.pdf
Thus bringing that together, 19 + 8.7 + 15.1 + 2 = 44.8 million. And with a quarterly burn of 5.1 million, as this currently stands that gives them a runway of 2 years. Simple math eh?
Let's also remember PSTI hasn't paid anything so far for the ARS NHP trials, so likely will not pay for a pivotal ARS trial.
I do hope we see something happen in the next 2 years.
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM
Mawson Finland Provides Update on Exploration Activities at Rajapalot • MFL • Aug 21, 2024 9:06 AM
Avant Technologies to Implement Robust Cybersecurity Measures for AI-Driven Healthcare Solutions • AVAI • Aug 21, 2024 8:00 AM